Company profile for Biocytogen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite™ mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamlin...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite™ mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
12th floor of Beijing Yizhuang Biomedical Park.\n
Telephone
Telephone
010-56315307
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250915935641/en/Biocytogen-Announces-ADC-Innovator-Tubulis-Has-Signed-Global-Exclusive-License-Agreement-for-Single-Antibody

BUSINESSWIRE
15 Sep 2025

https://www.businesswire.com/news/home/20250903434045/en/Biocytogen-Enters-into-Agreement-with-Merck-KGaA-Darmstadt-Germany-to-Advance-Antibody-Conjugated-Lipid-Based-Delivery-Solutions

BUSINESSWIRE
03 Sep 2025

https://www.businesswire.com/news/home/20250728835434/en/Biocytogen-Upgrades-Preclinical-Service-Platform-and-Launches-Revamped-Global-Website

BUSINESSWIRE
28 Jul 2025

https://www.businesswire.com/news/home/20250709188805/en/Biocytogen-Enters-into-Antibody-Licensing-Agreement-with-BeOne-Medicines-to-Accelerate-Innovative-Drug-Development

BUSINESSWIRE
09 Jul 2025

https://www.businesswire.com/news/home/20250617098086/en/Biocytogen-Responds-to-Harbour-BioMeds-Patent-Claims-RenNano-is-an-Independently-Developed-Platform-with-Distinct-Innovation-and-Full-Legal-Standing

BUSINESSWIRE
17 Jun 2025

https://www.businesswire.com/news/home/20250605093754/en/Biocytogen-Secures-Japan-Patent-for-RenMab-Platform-Expands-Global-Patent-Portfolio-for-RenMice-Fully-Human-AntibodyTCR-Platform

BUSINESSWIRE
05 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty